131 related articles for article (PubMed ID: 37646678)
21. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
22. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.
Chan KCA; Woo JKS; King A; Zee BCY; Lam WKJ; Chan SL; Chu SWI; Mak C; Tse IOL; Leung SYM; Chan G; Hui EP; Ma BBY; Chiu RWK; Leung SF; van Hasselt AC; Chan ATC; Lo YMD
N Engl J Med; 2017 Aug; 377(6):513-522. PubMed ID: 28792880
[TBL] [Abstract][Full Text] [Related]
24. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
[No Abstract] [Full Text] [Related]
27. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
[TBL] [Abstract][Full Text] [Related]
28. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
29. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
[TBL] [Abstract][Full Text] [Related]
30. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.
Cao SM; Liu Z; Jia WH; Huang QH; Liu Q; Guo X; Huang TB; Ye W; Hong MH
PLoS One; 2011 Apr; 6(4):e19100. PubMed ID: 21544243
[TBL] [Abstract][Full Text] [Related]
31. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
33. Combination of Plasma MIF and VCA-IgA Improves the Diagnostic Specificity for Patients With Nasopharyngeal Carcinoma.
Xue N; Xing S; Ma W; Sheng J; Huang Z; Xu Q
Technol Cancer Res Treat; 2020; 19():1533033820935773. PubMed ID: 32578505
[TBL] [Abstract][Full Text] [Related]
34. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China.
Ji MF; Sheng W; Cheng WM; Ng MH; Wu BH; Yu X; Wei KR; Li FG; Lian SF; Wang PP; Quan W; Deng L; Li XH; Liu XD; Xie YL; Huang SJ; Ge SX; Huang SL; Liang XJ; He SM; Huang HW; Xia SL; Ng PS; Chen HL; Xie SH; Liu Q; Hong MH; Ma J; Yuan Y; Xia NS; Zhang J; Cao SM
Ann Oncol; 2019 Oct; 30(10):1630-1637. PubMed ID: 31373615
[TBL] [Abstract][Full Text] [Related]
35. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
[TBL] [Abstract][Full Text] [Related]
38. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
39. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
[TBL] [Abstract][Full Text] [Related]
40. Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs.
Chen GH; Liu Z; Yu KJ; Coghill AE; Chen XX; Xie SH; Lin DF; Huang QH; Lu YQ; Ling W; Lin CY; Lu ZJ; Fan YY; Tang LQ; Sampson JN; Li H; King AD; Middeldorp JM; Hildesheim A; Cao SM
Clin Chem; 2022 Jul; 68(7):953-962. PubMed ID: 35325087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
